• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Esperion Therapeutics Inc.

    6/17/25 3:34:11 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ESPR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001953943
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Esperion Therapeutics, Inc.
    SEC File Number
    001-35986
    Address of Issuer
    3891 RANCHERO DRIVE, SUITE 150
    ANN ARBOR
    MICHIGAN
    48108
    Phone
    734-887-3903
    Name of Person for Whose Account the Securities are To Be Sold
    Halladay Benjamin
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    72298329.2519819946206/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/16/2025Restricted Stock VestingIssuerCheckbox not checked722906/16/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Benjamin Halladay
    3891 Ranchero Drive
    Suite 150
    Ann Arbor � MI � 48108
    Common03/18/202535355243.10
    Benjamin Halladay
    3891 Ranchero Drive
    Suite 150
    Ann Arbor � MI � 48108
    Common04/17/202587.71

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    06/17/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Benjamin Halladay.

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ESPR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ESPR

    DatePrice TargetRatingAnalyst
    12/18/2024$4.00Neutral
    Goldman
    12/17/2024$8.00Overweight
    Cantor Fitzgerald
    6/20/2024$2.50Neutral → Underperform
    BofA Securities
    1/3/2024Buy → Neutral
    BofA Securities
    11/20/2023Neutral
    JP Morgan
    8/1/2023Under Perform → Market Perform
    Northland Capital
    6/15/2023$1.25 → $4.00Underperform → Buy
    BofA Securities
    3/16/2023$1.00Market Perform → Under Perform
    Northland Capital
    More analyst ratings

    $ESPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

      3/25/24 4:41:30 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

      3/25/24 4:41:37 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

      3/25/24 4:41:29 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ESPR
    SEC Filings

    See more

    $ESPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ESPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Esperion Appoints Craig Thompson to Board of Directors

      ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel

      7/1/25 8:06:21 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

      ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA' s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Hetero USA has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limite

      6/2/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Participate in Upcoming June Investor Conferences

      ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET. Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Espe

      5/20/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

      7/1/25 8:14:50 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Esperion Therapeutics Inc.

      144 - Esperion Therapeutics, Inc. (0001434868) (Subject)

      6/17/25 3:34:11 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

      6/2/25 4:05:52 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Thompson John Craig

      4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      7/2/25 8:21:38 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Thompson John Craig

      3 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      7/2/25 8:18:47 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Looker Benjamin sold $7,398 worth of shares (6,422 units at $1.15), decreasing direct ownership by 2% to 401,241 units (SEC Form 4)

      4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      6/18/25 6:45:08 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Esperion Therapeutics with a new price target

      Goldman initiated coverage of Esperion Therapeutics with a rating of Neutral and set a new price target of $4.00

      12/18/24 7:29:57 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Esperion Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $8.00

      12/17/24 7:45:32 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $2.50

      6/20/24 7:33:38 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Esperion Appoints Craig Thompson to Board of Directors

      ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel

      7/1/25 8:06:21 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

      – Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive

      4/24/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

      ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion's research and development strategy. Discussions will highlight Esperion's advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indicati

      4/10/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Financials

    Live finance-specific insights

    See more
    • HLS Therapeutics Announces Q1 2025 Financial Results

      Total Product revenue grew 5% compared to Q1 2024, with growth across both the US and CanadaCanadian Product revenue grew 13% (in local currency) compared to Q1 2024, driven by 34% year-over-year growth in Vascepa net sales Adjusted EBITDA grew 41% (or 78% excluding royalty revenue) compared to Q1 2024HLS expands Cardiovascular portfolio by securing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion TherapeuticsTORONTO, May 8, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended Marc

      5/8/25 6:32:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Reports First Quarter 2025 Financial Results

      – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million – – Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes – – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the first quarter ended March 31, 202

      5/6/25 6:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Report First Quarter 2025 Financial Results on May 6

      ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company f

      4/23/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/14/24 8:42:21 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/12/24 2:23:13 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/4/24 1:33:59 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care